Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV

Stem Cell Transplant Complications Clinical Trial

— REVIRAL2  

Official title:

Randomized, Double-blind, Placebo-controlled Trial of the Safety, Tolerability, and Efficacy of RV521 in the Treatment of Adult Subjects Who Have Undergone Hematopoietic Cell Transplantation (HCT) With a Documented Upper Respiratory Tract Infection (URTI) With Respiratory Syncytial Virus (RSV)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04267822
• Other study ID #: REVC006
• Secondary ID: C5241011
• Status: Withdrawn
• Phase: Phase 2
• Start date: June 15, 2020
• Est. completion date: July 31, 2023

Study information

• Verified date: May 2023
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RV521 is to being developed to treat RSV infection and disease in susceptible individuals at high risk for complications. This is an international, multicenter, placebo-controlled study. Eligible subjects are adults with a documented symptomatic RSV infection who have undergone HCT transplantation and are moderately to severely immunocompromised. Qualified subjects will be randomized in a 1:1 ratio to receive RV521 or placebo, twice daily for 10 days.

Description:

The purpose of this study is to compare the viral load, safety, tolerability, and clinical efficacy of RV521 compared to placebo. This is a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled study. Up to 200 adult subjects with a documented symptomatic RSV URTI who have undergone HCT within 1 year of randomization and who are moderately to severely immunocompromised will be randomized.

Qualified subjects will be randomized in a 1:1 ratio to receive RV521 capsules or matching placebo twice daily for 10 days. After the completion of the 10-day double-blind treatment period, subjects will be followed for an additional 28 days. Study drug may be taken on an outpatient or inpatient basis, depending on clinical status and site practices. Randomization will be stratified by type of HCT graft and ALC count. There are 9 clinic visits planned for this study.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: July 31, 2023
• Est. primary completion date: June 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Has undergone autologous or allogeneic HCT using any conditioning regimen within 1 year of randomization. Subjects who have undergone HCT more than 1 year before Randomization are eligible if all other inclusion/exclusion criteria are satisfied and under at least one of the following conditions:

1. Diagnosed with Chronic Graft-vs-Host Disease (GVHD), or

2. Has used systemic corticosteroids in the 30 days prior to RSV infection

2. Has moderate to severe immunocompromise, defined as a score = 5 on the ISI-RSV and/or an ALC of = 500 cells/ mm3

3. Documentation of positive RSV infection in the upper airway

Exclusion Criteria:

1. Use of non-marketed investigational agents within 30 days, OR use of an investigational monoclonal anti-RSV antibodies within 4 months or 5 half-lives of screening, whichever is longer, OR use of any investigational RSV vaccines after HCT.

2. Receiving a prescription, OTC, or herbal medication that is a potent inducer or inhibitor of CYP3A4, within 2 weeks of Randomization.

3. Receiving a prescription, OTC, or herbal medication that is a substrate of CYP3A4 with a narrow therapeutic index where monitoring blood levels is not possible.

4. Known chronic infection with hepatitis B, C, or HIV.

5. Is in the pre-engraftment period during RSV infection.

6. Admitted to the hospital primarily for lower respiratory tract disease of any cause as determined by the Investigator.

7. Any condition requiring mechanical ventilation or vasopressor support at the time of randomization.

8. Clinically significant bacteremia or fungemia within 5 days prior to Screening that has not been adequately treated.

9. Clinically significant bacterial, fungal, or viral pneumonia within 2 weeks prior to Screening that has not been adequately treated.

10. Excessive nausea/vomiting at Screening or an inability to swallow capsules.

11. Elevation of hepatic enzymes or renal compromise.

Related Conditions & MeSH terms

• Communicable Diseases
• Infections
• Lower Resp Tract Infection
• Respiratory Syncytial Virus Infections
• Respiratory Tract Infections
• RSV Infection
• Stem Cell Transplant Complications

Intervention

Drug:
• RV521 oral tablet
Each RV521 dose is four 50 mg dry powder blend capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
• Placebo oral tablet
Each placebo dose is four capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of subjects with a progression to Lower Respiratory Tract Complication (LRTC) during the study	Progression to LRTC during the study defined as one of the following: Primary LRTI caused by RSV; Secondary bacterial LRTI; LRTI caused by another pathogen; LRTC of unknown etiology	Pre-dose baseline (Day 1) through Visit 8 (Day 28)
Primary	Change in RSV nasal viral load (via RT-qPCR)	RSV change measured by the time-weighted average (DAVG) viral load using RT qPCR	Pre-dose baseline (Day 1) through study completion; up to Visit 8 (Day 28)
Secondary	Percent of participants who experience AEs, TEAEs, SAEs and withdrawals due to TEAEs	Safety analyses will include a summary of AEs, including but not limited to n (%) of subjects in each treatment group and overall.	First dose of study drug through Visit 8 (Day 28)
Secondary	Evaluate safety and tolerability of RV521 by assessing changes from baseline in systolic and diastolic BP (vital sign parameters)	BP will be collected in mm Hg. Quantitative variables will be summarized used the statistics n, mean, standard deviation, median, minimum and maximum.	Baseline through Visit 8 (Day 28)
Secondary	Evaluate safety and tolerability of RV521 by assessing changes from baseline in body temperature (vital sign parameters)	Body Temperature will be collected in degrees Fahrenheit (°F) or degrees Celsius (°C). Quantitative variables will be summarized used the statistics n, mean, standard deviation, median, minimum and maximum.	Baseline through Visit 8 (Day 28)
Secondary	Evaluate safety and tolerability of RV521 by assessing changes from baseline in respiration rate (vital sign parameters)	Respiration rate will be measured in breaths per minute. Quantitative variables will be summarized used the statistics n, mean, standard deviation, median, minimum and maximum.	Baseline through Visit 8 (Day 28)
Secondary	Evaluate safety and tolerability of RV521 by assessing changes from baseline in pulse/heart rate (vital sign parameters)	Heart rate will be measured in beats per minute. Quantitative variables will be summarized used the statistics n, mean, standard deviation, median, minimum and maximum.	Baseline through Visit 8 (Day 28)
Secondary	Evaluate safety and tolerability of RV521 by assessing changes from baseline weight/BMI	Weight and height will be collected and combined to report BMI	Baseline through Visit 8 (Day 28)
Secondary	Evaluate the proportion of subjects with changes and shifts in hematology/clinical chemistry/urinalysis laboratory values (laboratory tests read by a central lab) from baseline.	Results at each visit will be summarized using the statistics n, mean, standard deviation, median, minimum and maximum. Also, change from baseline will also be summarized by post baseline visits.	Collected at Visit 2/Day 1 (pre-dose), Visit 4/Day 3, Visit 6/Day 14 and Visit 8/Day 28
Secondary	Evaluate the proportion of subjects with changes in ECG measurements and changes in clinical impression from baseline	ECGs will be taken with a centrally supplied ECG machine and electronically transmitted to a central ECG repository. ECG will only be evaluated by the Investigator for normal, abnormal NCS and abnormal CS.; Parameters collected will be: Ventricular Heart Rate (bpm); PR Interval (msec); QRS Interval (msec); QT Interval (msec); QTcB Interval (msec); Results at each visit will be summarized using the statistics: n (number of observations), mean, SD, median, minimum and maximum.	Measurements will be taken at Day 1/Visit 2 (pre-dose and at 5-hours post-dose), on Day 3/Visit 4 (at 5 hours post-dose), and at Visit 6 (Day 14)
Secondary	Relationship between plasma exposures of RV521 and RSV viral loads measured in nasal swabs by RT-qPCR	Nasal swabs will be collected for analysis of viral load and RSV F protein gene sequencing at a central laboratory. Viral load will be assessed at intervals from nasal swabs by RT-qPCR.	Pre-dose baseline (Day 1) and every visit through Visit 8 (Day 28)
Secondary	Relationship between plasma exposures of RV521 and RSV viral loads measured in nasal swabs by CBIA	Nasal swabs will be collected for analysis of viral load and RSV F protein gene sequencing at a central laboratory. Viral load will be assessed at intervals from nasal swabs by CBIA.	Pre-dose baseline (Day 1) and every visit through Visit 8 (Day 28)
Secondary	Mean change in RSV viral load assessed via CBIA	change measured by the time weighted average (DAVG) viral load using CBIA	Pre-dose baseline (Day 1) through study completion; up to Visit 8 (Day 28)
Secondary	Mean change from baseline in viral RNA shedding	RSV assessed via nasal swabs collected at each visit and analyzed at a central laboratory.	Pre-dose baseline (Day 1) through study completion; up to Visit 8 (Day 28)
Secondary	Proportion of subjects who no longer shed RSV assessed by both RT-qPCR and CBIA at each timepoint	RSV assessed via nasal swabs collected at each visit and analyzed at a central laboratory.	Pre-dose baseline (Day 1) through study completion; up to Visit 8 (Day 28)
Secondary	Time to improvement in RSV-related symptoms	Defined as all symptoms present at initiation of therapy are mild or no longer present. (absent/resolved)	Daily from baseline (Day 1) through Visit 8 (Day 28)
Secondary	Time to total resolution of all RSV-related symptoms	Defined as all symptoms are no longer present.	Daily from baseline (Day 1) through Visit 8 (Day 28)
Secondary	Proportion of days with lowest daily SpO2 = 90% on room air	SpO2 measured at every visit. For subjects on oxygen or who are mechanically ventilated may have this waived.	Daily from baseline (Day 1) through Visit 8 (Day 28)
Secondary	Number of days where supplementary oxygen was required	Use of daily supplementary oxygen will be collected throughout the study.	Baseline (Day 1) through Visit 8 (Day 28)
Secondary	Proportion of subjects who require hospitalization during the study	Daily hospitalization utilization will be collected	Baseline (Day 1) through Visit 8 (Day 28)
Secondary	Mean number of days of hospitalization during the study	Daily hospitalization utilization will be collected	Baseline (Day 1) through Visit 8 (Day 28)
Secondary	Proportion of subjects requiring ICU	Daily ICU utilization will be collected	Baseline (Day 1) through Visit 8 (Day 28)
Secondary	Mean number of days in ICU	Daily ICU utilization will be collected	Baseline (Day 1) through Visit 8 (Day 28)
Secondary	Proportion of subjects requiring mechanical ventilation	Daily mechanical ventilation requirements will be collected	Baseline (Day 1) through Visit 8 (Day 28)
Secondary	Number of subjects who experience death (all-cause mortality)	Patient outcome will be followed and collected	First dose of study drug through Visit 8 (Day 28)
Secondary	Number of subjects who experience death attributable to LRTC	Patient outcome will be followed and collected	First dose of study drug through Visit 8 (Day 28)